(tert-butoxy)-N-[1-aza-2-(3-methyl(2-thienyl))vinyl]carboxamide | 113874-61-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 杂芳族化合物
• 英文名称: (tert-butoxy)-N-[1-aza-2-(3-methyl(2-thienyl))vinyl]carboxamide
• 英文别名: N'-[(E)-(3-methylthiophen-2-yl)methylidene]tert-butoxycarbohydrazide；tert-butyl N-[(3-methylthiophen-2-yl)methylideneamino]carbamate
• CAS: 113874-61-6
• 化学式: C₁₁H₁₆N₂O₂S
• 分子量: 240.326
• InChiKey: CVMMPCIAKJAFNS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  78.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (tert-butoxy)-N-[1-aza-2-(3-methyl(2-thienyl))vinyl]carboxamide 在 sodium cyanoborohydride 、 对甲苯磺酸 作用下， 以 四氢呋喃 为溶剂， 反应 4.0h， 生成 (tert-butoxy)-N-{[7-chloro-4-hydroxy-2-(pyrrolidinylcarbonyl)(3-quinolyl)]-N-[(3-methyl(2-thienyl))methyl]carbonylamino}carboxamide
  参考文献：
  名称：

  Pyridazinoquinolinetriones as NMDA Glycine-Site Antagonists with Oral Antinociceptive Activity in a Model of Neuropathic Pain

  摘要：

  A series of 7-chloro-2,3-dihydro-2-[1-(pyridinyl)alkyl]-pyridazino[4,5-b]quinoline-1,4,10(5H)-triones were synthesized and found to have potent activity at the glycine site of the NMDA receptor. In some cases, these compounds possessed poor aqueous solubility that may have contributed to poor rat oral bioavailability. Subsequently, compounds have been identified with improved aqueous solubility and oral bioavailability. Several of these compounds were examined in a rat chronic constrictive injury (CCI) model of neuropathic pain and found to have potent activity when dosed orally.

  DOI：

  10.1021/jm060212s
• 作为产物：
  描述：

  3-甲基噻吩醛 、 肼基甲酸叔丁酯 在 盐酸 作用下， 以 四氢呋喃 为溶剂， 以80%的产率得到(tert-butoxy)-N-[1-aza-2-(3-methyl(2-thienyl))vinyl]carboxamide
  参考文献：
  名称：

  Pyridazinoquinolinetriones as NMDA Glycine-Site Antagonists with Oral Antinociceptive Activity in a Model of Neuropathic Pain

  摘要：

  A series of 7-chloro-2,3-dihydro-2-[1-(pyridinyl)alkyl]-pyridazino[4,5-b]quinoline-1,4,10(5H)-triones were synthesized and found to have potent activity at the glycine site of the NMDA receptor. In some cases, these compounds possessed poor aqueous solubility that may have contributed to poor rat oral bioavailability. Subsequently, compounds have been identified with improved aqueous solubility and oral bioavailability. Several of these compounds were examined in a rat chronic constrictive injury (CCI) model of neuropathic pain and found to have potent activity when dosed orally.

  DOI：

  10.1021/jm060212s